Form 4: Ionis Pharmaceuticals Director Receives 2025 Equity Compensation

Ionis Pharmaceuticals Director Joan E. Herman was granted 11,518 non-qualified stock options and 5,220 restricted stock units as part of her 2025 equity compensation, totaling no more than $450,000.

Summary

• Joan E. Herman, a Director at Ionis Pharmaceuticals Inc. (IONS), was granted equity compensation on July 1, 2025.
• The compensation includes 11,518 non-qualified stock options with an exercise price of $39.94 per share.
• Additionally, 5,220 Restricted Stock Units (RSUs) were granted, each representing a contingent right to receive one share of Ionis common stock or its equivalent cash value.
• These grants were made pursuant to the Company's Non-Employee Director Compensation Policy, which caps annual equity compensation for non-employee Directors at no more than $450,000 based on aggregate grant date fair value (FASB Topic ASC 718).
• Both the stock options and RSUs vest 100% on the earlier of the first anniversary of the grant date or the next regularly scheduled annual meeting of stockholders.
• The stock options become exercisable upon vesting and expire on June 30, 2035.
• RSU shares will be delivered to the reporting person on July 15th following their vesting date.

Sentiment

Score: 7

Explanation: The document reports a routine equity compensation grant to a director, which is a standard practice for aligning interests and does not indicate any negative or unexpected events. It reflects normal corporate operations.

Positives

• The equity grants align the interests of Director Joan E. Herman with those of shareholders, as her compensation is tied to the company's stock performance.
• The compensation is part of a defined Non-Employee Director Compensation Policy, indicating structured and transparent governance regarding executive and director remuneration.

Future Outlook

The granted stock options and restricted stock units are subject to future vesting, which will occur on the earlier of the first anniversary of the grant date or the next regularly scheduled annual meeting of stockholders. This indicates a future increase in beneficial ownership for the director upon vesting.

Management Comments

• Grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718, pursuant to the Company's Non-Employee Director Compensation Policy.

Industry Context

The granting of equity compensation to non-employee directors is a standard practice across publicly traded companies, particularly within the biotechnology and pharmaceutical sectors. This mechanism is widely used to attract and retain qualified board members, aligning their financial interests with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The structure of director equity compensation, including stock options and restricted stock units with vesting schedules, is consistent with common practices observed in the broader pharmaceutical and biotech industry.
• The use of a defined compensation policy and a cap on annual equity value (e.g., $450,000) reflects a structured approach to governance, comparable to policies at companies like Amgen or Gilead Sciences, which also utilize equity-based incentives for their non-executive directors to foster long-term alignment.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the financial interests of Director Joan E. Herman with those of the shareholders, potentially encouraging decisions that enhance long-term stock value.

Next Steps

• Vesting of the 11,518 non-qualified stock options and 5,220 Restricted Stock Units on the earlier of July 1, 2026, or the next annual meeting of stockholders.
• Delivery of shares for vested Restricted Stock Units on July 15th following the vesting date.

Key Dates

Recommendation

Keywords

Ionis Pharmaceuticals, IONS, Director Compensation, Stock Options, Restricted Stock Units, RSU, Equity Grant, SEC Form 4, Insider Transaction, Corporate Governance